Johnson & Johnson (JNJ) reported "statistically significant" topline results Tuesday from a phase 3 study evaluating the combination of Rybrevant and Lazcluze as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

The pharmaceutical company said the combination regimen, which avoids the use of chemotherapy, met the final pre-specified secondary endpoint of overall survival.

It also said the trial demonstrated "clinically meaningful and statistically significant" improvement in overall survival compared with AstraZeneca's (AZN) osimertinib, which it said is the current standard of care.